Cargando…

Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4

Natural killer (NK) cells are a noteworthy lymphocyte subset in cancer adoptive cell therapy. NK cells initiate innate immune responses against infections and malignancies with natural cytotoxicity, which is independent of foreign antigen recognition. Based on these substantive features, genetically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamali, Arezoo, Hadjati, Jamshid, Madjd, Zahra, Mirzaei, Hamid Reza, Thalheimer, Frederic B., Agarwal, Shiwani, Bonig, Halvard, Ullrich, Evelyn, Hartmann, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483584/ https://www.ncbi.nlm.nih.gov/pubmed/32983147 http://dx.doi.org/10.3389/fimmu.2020.02028

Ejemplares similares

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

In vivo generated human CAR T cells eradicate tumor cells
por: Agarwal, Shiwani, et al.
Publicado: (2019)

In vivo generation of CAR T cells in the presence of human myeloid cells
por: Ho, Naphang, et al.
Publicado: (2022)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
por: Jafarzadeh, Leila, et al.
Publicado: (2020)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors
por: Ghahri-Saremi, Navid, et al.
Publicado: (2021)

Crosstalk between autophagy and metabolic regulation of (CAR) T cells: therapeutic implications
por: Panahi Meymandi, Ahmad Reza, et al.
Publicado: (2023)

The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
por: Akbari, Behnia, et al.
Publicado: (2023)

PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer
por: Akbari, Behnia, et al.
Publicado: (2023)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
por: Soltantoyeh, Tahereh, et al.
Publicado: (2021)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
por: Ramezani, Faezeh, et al.
Publicado: (2023)

Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
por: Gilg, Andrea, et al.
Publicado: (2021)

Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
por: Masoumi, Elham, et al.
Publicado: (2020)

Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity
por: Oberoi, Pranav, et al.
Publicado: (2020)

CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
por: Ng, Yu Yang, et al.
Publicado: (2019)

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia
por: Albinger, Nawid, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Dendritic cells loaded with exosomes derived from cancer stem cell‐enriched spheroids as a potential immunotherapeutic option
por: Naseri, Marzieh, et al.
Publicado: (2021)

Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines
por: Kulemzin, Sergey V., et al.
Publicado: (2019)

Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors
por: Jamali, Arezoo, et al.
Publicado: (2019)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy
por: Arab, Samaneh, et al.
Publicado: (2019)

Novel immune modulators used in hematology: impact on NK cells
por: Krieg, Stephanie, et al.
Publicado: (2013)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Immunotherapy with NK cells: recent developments in gene modification open up new avenues
por: Reindl, Lisa Marie, et al.
Publicado: (2020)

CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes
por: Kapitza, Laura, et al.
Publicado: (2023)

Albumin Modifies Responses to Hematopoietic Stem Cell Mobilizing Agents in Mice
por: Danner, Eva, et al.
Publicado: (2019)

CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust
por: Wiercinska, Eliza, et al.
Publicado: (2021)

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
por: Prommersberger, Sabrina, et al.
Publicado: (2021)

Frequencies of CD4+ T Regulatory Cells and their CD25(high) and FoxP3(high) Subsets Augment in Peripheral Blood of Patients with Acute and Chronic Brucellosis
por: Bahador, Abbas, et al.
Publicado: (2014)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6q5lfjrdku0gaiac49bmb7k5ku